Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Estramustine phosphate sodium.

A R Hauser, R Merryman

    Drug Intelligence & Clinical Pharmacy
    |May 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Estramustine phosphate effectively treats advanced prostate cancer, particularly in patients resistant to other hormonal therapies. While generally safe, potential gastrointestinal and cardiovascular side effects require monitoring.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Cytotoxicity and virulence attributes of <i>Pseudomonas aeruginosa</i> isolates from case reports of patients with necrotizing pneumonia.

    Respiratory medicine case reports·2025
    Same author

    Identification of Clostridium innocuum hypothetical protein that is cross-reactive with C. difficile anti-toxin antibodies.

    Anaerobe·2022
    Same author

    ASC acts in a caspase-1-independent manner to worsen acute pneumonia caused by Pseudomonas aeruginosa.

    Journal of medical microbiology·2018
    Same author

    Pseudomonas aeruginosa induces type-III-secretion-mediated apoptosis of macrophages and epithelial cells.

    Infection and immunity·1999
    Same author

    Pseudomonas aeruginosa gene products PilT and PilU are required for cytotoxicity in vitro and virulence in a mouse model of acute pneumonia.

    Infection and immunity·1999
    Same author

    Another toxic shock syndrome. Streptococcal infection is even more dangerous than the staphylococcal form.

    Postgraduate medicine·1998
    Same journal

    Profile of prescription medication in a pediatric population.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    SI units in drug therapeutics.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Physicians' review of significant interventions by clinical pharmacists in inpatient care.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Possible interaction of ranitidine with phenytoin.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Famotidine-associated mental confusion in elderly patients.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Intravenous self-administration of elemental mercury: efficacy of dimercaprol therapy.

    Drug intelligence & clinical pharmacy·1988
    See all related articles

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • Estramustine phosphate is an FDA-approved oral medication for palliative treatment of metastatic or progressive prostate cancer.
    • It's a conjugate of 17 beta-estradiol and nitrogen mustard, but the specific contribution of each component to its efficacy is not fully understood.

    Purpose of the Study:

    • To evaluate the efficacy and side effect profile of estramustine phosphate in prostate cancer treatment.
    • To assess its effectiveness in patients with varying degrees of hormonal therapy resistance.

    Main Methods:

    • Clinical response rates were assessed in patients with advanced stage D prostate cancer.
    • Efficacy was compared between patients with no prior hormonal therapy and those refractory to conventional hormonal therapy.
    • Adverse effects were documented and compared to those of diethylstilbestrol.

    Related Experiment Videos

    Main Results:

    • Objective response rates of 60-90% were observed in hormone-naive advanced prostate cancer patients.
    • In estrogen-resistant patients, response rates of 20-30% were achieved, indicating promise in this group.
    • Concurrent use with other chemotherapeutic agents did not appear to enhance therapeutic efficacy.

    Conclusions:

    • Estramustine phosphate demonstrates significant efficacy in advanced prostate cancer, especially in estrogen-resistant cases.
    • The drug's adverse effects are comparable to diethylstilbestrol, with gastrointestinal and cardiovascular issues being most prominent.
    • Estramustine phosphate offers a valuable treatment option for specific prostate cancer patient populations.